Global Community

DXN Holdings Berhad’s latest boardroom move looks more meaningful than a routine corporate appointment. The group has appointed its CEO, Prajith Pavithran , as its new Executive Director , a move that can be seen as strengthening the connection between daily operations and board-level decision-making.Read more

Every AI Chip on the Planet Passes Through One Company's Front Door. That Should Terrify You and Excite You in Equal Measure.Read more

Alibaba, once the undisputed titan of China’s e-commerce space, has faced headwinds in recent years—from regulatory pressures to slowing consumer demand and an overextension into offline-heavy businesses. However, the company is entering a pivotal transition.Read more

Hololive's Cover Corporation continues to experience margin compression due to: Excessive spending, increased annual salaries with employees working with Unreal and their Metaverse project plus a shortfall after a delayed response to Japan-U.S. tariff trade issues. Flat streaming revenue and negative concert/event results in Q3 shows the net result of loss of talent and a general pullback of streaming by talent after management rotated their revenue focus.Read more

When investors look at the Malaysian construction and property sectors, giants like MRCB or Berjaya Corporation often dominate the conversation. However, peering into the micro-cap space often reveals hidden value.Read more

Investment Thesis DefenCath's regulatory moat (only FDA-approved antimicrobial CLS in the U.S., NCE+GAIN exclusivity through 2033, composition patent to 2042) is intact and the 72% real-world CRBSI reduction is standard-of-care quality data; the TDAPA pricing step-down is a commercial mechanics event, not a competitive displacement event The stock at $7.02 prices in approximately the bear case ($6.54), meaning investors are effectively receiving the REZZAYO prophylaxis Phase III binary and the DefenCath TPN pipeline for free — an unusual asymmetry for a cash-flow-positive commercial pharma company Operating cash flow of $175M in FY2025 and $148.5M in cash provides full self-funding of pipeline without dilution risk, and the $75M buyback at current prices represents management's explicit capital allocation conviction about intrinsic value The Melinta acquisition was well-priced ($30M goodwill on $391M identified intangibles) and adds an annualizing $130M+ revenue stream with shared call points that provide SG&A leverage as the combined platform scales Post-TDAPA recovery in 2027 (3x–5x higher add-on payment vs. H2 2026 per management, plus Medicare Advantage contracting upside not in guidance) provides a clearly identified catalyst path back to re-rating independent of pipeline success Risk Considerations ReSPECT Phase III failure (data Q2 2026) would eliminate ~$221M of base case rNPV, trigger impairment of the $143M IPR&D intangible, and likely reset the stock to the $5.60 52-week low or below — this is the primary binary risk and is near-term Customer concentration at 79% revenue from three accounts is structurally dangerous; any publicly announced reduction in DefenCath orders from a major dialysis organization would be a material negative event with little warning The Q4 GAAP EPS miss ($0.16 vs.Read more

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more

NCT Alliance Berhad (“NCT”) has entered a new phase in its corporate journey with the appointment of Mr Ong Chou Wen as Chief Executive Officer, effective 1 April 2026. The leadership change comes at a meaningful juncture for the property developer, as the market continues to reward companies that can combine project execution, balance sheet discipline, and sharper commercial positioning in an increasingly competitive operating environment.Read more

Rating: Speculative Buy / High Risk Style: AI infrastructure “picks-and-shovels” growth name Core debate: Is AAOI a genuine bottleneck asset in AI networking, or a cyclical optics supplier temporarily enjoying peak demand and peak multiples? Executive view Applied Optoelectronics is no longer just a small-cap optical component company.Read more